Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

BioInvent International

2.31 SEK-11.66 %19.11. klo 17.04
Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-11.66 %
-90.13 %
-90.15 %
-89.87 %
-92.14 %
-92.02 %
-84.80 %
-94.83 %
-99.76 %

BioInvent International is a biotechnology company focused on the development of antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
152.01M SEK
Turnover
631.72K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
1.12.
2026

Extraordinary general meeting '27

4.3.
2027

Annual report '26

29.4.
2027

Interim report Q1'27

Press release09.11.2026 klo 12.17

BioInvent to Participate in Upcoming Investor Conferences

BioInvent International
Press release06.11.2026 klo 17.15

Redeye: BioInvent: Fair Value Adjusted for Rights Issue Terms

BioInvent International
Regulatory press release06.11.2026 klo 00.05

BioInvent announces final terms for the Rights Issue of approximately SEK 430 million and informs that the Issue is fully guaranteed by additional top guarantee undertakings

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release30.10.2026 klo 18.30

Supplement: Notice to Extraordinary General Meeting in BioInvent International AB

BioInvent International
Press release30.10.2026 klo 15.13

Redeye: BioInvent (Q3 Review): Rights Issue to Fund Part C

BioInvent International
BioInvent, Audiocast, Q3'26
Webcast29.10.2026 klo 16.00

BioInvent, Audiocast, Q3'26

BioInvent International
Press release29.10.2026 klo 13.19

Redeye: BioInvent: SEK430m Rights Issue, but Owner Support Is Thin

BioInvent International
Regulatory press release28.10.2026 klo 19.17

BioInvent International AB: Interim report January – September, 2026

BioInvent International
Regulatory press release28.10.2026 klo 19.16

Notice to Extraordinary General Meeting in BioInvent International AB

BioInvent International
Regulatory press release28.10.2026 klo 19.15

BioInvent resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January – September 2026

BioInvent International
Press release27.10.2026 klo 15.15

Invitation to presentation of BioInvent’s Interim Report January – September 2026

BioInvent International
Press release26.10.2026 klo 16.17

Redeye: BioInvent: Larger Cohort Confirms BI-1808 Efficacy

BioInvent International
Regulatory press release24.10.2026 klo 10.00

BioInvent's BI-1808 and KEYTRUDA® Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

BioInvent International
Press release19.10.2026 klo 15.22

Redeye: BioInvent: New RECIST Context to BI-1808 Data

BioInvent International
Press release19.10.2026 klo 01.05

BioInvent to present BI-1808 data in platinum-resistant recurrent ovarian cancer at ESMO 2026

BioInvent International
Press release15.10.2026 klo 17.00

BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

BioInvent International
Regulatory press release12.10.2026 klo 10.45

BioInvent International AB announces that its CFO will retire in 2027

BioInvent International
Press release10.09.2026 klo 10.00

BioStock: BioInvent International to Present at Investing in Life Science on September 22

BioInvent International
Press release01.09.2026 klo 18.55

Redeye: BioInvent (Q2 Review): A Quarter of Positive Clinical Read-Outs

BioInvent International
Regulatory press release27.08.2026 klo 09.00

BioInvent International AB: Interim report January - June 2026

BioInvent International